Screener
ArriVent BioPharma, Inc. AVBP Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock $0.0001 par value, 200,000,000 shares authorized; 45,308,941 and 42,452,251 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 5 | 4 |
| Additional paid-in capital | 772,206 | 711,847 |
| Accumulated deficit | (447,961) | (404,641) |
| Accumulated other comprehensive income (loss) | (270) | 14 |
| Total stockholders’ equity | 323,980 | 307,224 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s common stock?
- ArriVent BioPharma, Inc. (AVBP) reported common stock of $5K in Q1 2026.
- How has ArriVent BioPharma, Inc.'s common stock changed year-over-year?
- ArriVent BioPharma, Inc.'s common stock increased by 25.0% year-over-year, from $4K to $5K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about ArriVent BioPharma, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude